Difference between revisions of "AstraZeneca"
Jump to navigation
Jump to search
(SW: The Strange Profits from a Re-Branded Cancer Drug) |
(tidy) |
||
| Line 13: | Line 13: | ||
[[Category:Pharmaceutical industry]] | [[Category:Pharmaceutical industry]] | ||
*Peter Rost, MD, "[http://www.counterpunch.org/rost04182007.html The Strange Profits from a Re-Branded Cancer Drug: How to Sell Drugs at $4,200 a Dose]", ''Counterpunch'', April 18, 2007. | *Peter Rost, MD, "[http://www.counterpunch.org/rost04182007.html The Strange Profits from a Re-Branded Cancer Drug: How to Sell Drugs at $4,200 a Dose]", ''Counterpunch'', April 18, 2007. | ||
| − | |||
Revision as of 07:35, 20 April 2007
AstraZeneca is one of the world's largest pharmaceutical companies. The company specialises in drugs for gastrointestinal, cardiovascular, and oncology therapeutic areas. The company has accused animal rights activists of forcing its research operations to Asia and South America [1].
AstraZeneca is also the creator of National Breast Cancer Awareness Month.
Donate their products to AmeriCares. [2]
Contact details
External Links
- Heather Thomlinson, "European market is inferior, says AstraZeneca", Guardian (UK), October 22, 2004.
- "AZ raises Crestor global PR clout", PR Week, May 20, 2005. (Sub req'd). (This article refers to AZ's PR team handling the controversy over its cholesterol-lowering drug Crestor.)
- Peter Rost, MD, "The Strange Profits from a Re-Branded Cancer Drug: How to Sell Drugs at $4,200 a Dose", Counterpunch, April 18, 2007.
